Oliver Thewalt

    Oliver Thewalt

    Theoretical Physics | Quantum Biology | Dark Matter Research | Energy Consulting | Creation of Hydrogen ATOM in the Higgs Field >> Vote for Nobel Prize


    Doubts about the validity of cancer research by CRISPR CAS9

    I have doubts about the validity of this research, but I am not sure before I have done more research about the CRISPR CAS9 topic: in general there is a tendency to misuse the CRISPR CAS9 research area in order to control and manipulate patients/nature:

    look up for instance who got the Prinzessin-von-Asturien Prize and with whom (Google) this foundation is partnering!

    This is doubtful:

    "Two women credited with creating revolutionary gene-editing technology have won this year’s Princess of Asturias Award for Technical and Scientific Research.

    Emmanuelle Charpentier and Jennifer Doudna”: have developed a way to give scientists the power to remove or add genetic material at will."





    Emmanuelle Charpentier y Jennifer Doudna, Premio Princesa de Asturias de Investigación Científica y Técnica



    The Princess of Asturias Foundation partners up with the Google Arts & Culture project



    We should at first start to understand the phenomenon cancer, before we propose a solution to this problem!

    I think that there is no cancer as such, the approach to treat cancer as a disease is not very helpful: what is missing in western science it to understand that there are mind and environment (also radiation and toxic substances) induced "quasi inflammatory" metastatic states on quantum level ..... ~Quantum Biology

    CRISPR, the disruptor
    A powerful gene-editing technology is the biggest game changer to hit biology since PCR. But with its huge potential come pressing concerns.


    Information Biology by Quantum Biology - Cancer Research


    Research: Cause of cancer, quantum biology


    Cytotoxic T Cells on Patrol


    CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials



    DOI: http://dx.doi.org/10.7554/eLife.24179
    Published March 24, 2017

    The Maternal Embryonic Leucine Zipper Kinase (MELK) has been reported to be a genetic dependency in several cancer types. MELK RNAi and small-molecule inhibitors of MELK block the proliferation of various cancer cell lines, and MELK knockdown has been described as particularly effective against the highly-aggressive basal/triple-negative subtype of breast cancer. Based on these preclinical results, the MELK inhibitor OTS167 is currently being tested as a novel chemotherapy agent in several clinical trials. Here, we report that mutagenizing MELK with CRISPR/Cas9 has no effect on the fitness of basal breast cancer cell lines or cell lines from six other cancer types. Cells that harbor null mutations in MELK exhibit wild-type doubling times, cytokinesis, and anchorage-independent growth. Furthermore, MELK-knockout lines remain sensitive to OTS167, suggesting that this drug blocks cell division through an off-target mechanism. In total, our results undermine the rationale for a series of current clinical trials and provide an experimental approach for the use of CRISPR/Cas9 in preclinical target validation that can be broadly applied.




    Read More: